The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial.

ABSTRACT:

Background

Nephrotic syndrome (NS) is a common form of glomerular disease in children, characterized by a high propensity for relapse. Prolonged use of glucocorticoids (GCs) can result in various side effects. Rituximab (RTX) may be considered as an initial treatment option for primary nephrotic syndrome in pediatric patients.

Methods

We conducted a prospective, single-center, randomized controlled trial (RCT) to evaluate whether the initial use of RTX monotherapy is superior to GC therapy in treating pediatric idiopathic NS and to assess its safety. The primary outcome and secondary outcomes were compared between the two groups.

Results

A total of 24 pediatric patients were included in the study, comprising 19 males and 5 females. After six weeks of treatment, the co

SUBMITTER: Sheng AQ 

PROVIDER: S-EPMC12057790 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature